Synlogic Inc · OTC:SYBX
Synlogic — Mirna Therapeutics — Merger or Acquisition (June 2017)
25 slides from Synlogic's merger presentation, Jun 9, 2017
Slide 1: Synlogic Corporate Overview
Synlogic Corporate Overview JC Gutierrez-Ramos, President and CEO June 2017 A Novel Class of Living Medicines Synthetic BioticTM medicines to perform metabolic functions to treat diseases throughout the body
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Additional Information
Additional Information This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed trans
Slide 4: Synthetic Biotics: A Novel Class of Living Medicines
Synthetic BioticsTM: A Novel Class of Living Medicines Synthetic Biology + Bacteria = Synthetic Biotic Medicine Therapeutic delivered locally to treat systemic diseases Synthetic Engineered bacteria With designed genetic circuits To degrade metabolites that induce disease or synthesize substances to
Slide 5: Synlogic announced merger with Mirna Therapeutics
Synlogic announced merger with Mirna Therapeutics to become Nasdaq listed company The go forward company will operate as Synlogic, Inc. Expected to close 3Q 2017 subject to the approval of the stockholders of each company and the satisfaction or waiver of other customary conditions Expected ownershi
Slide 6: Synlogic Management Team
Synlogic Management Team: From Funding of Platform to Clinic in Less than Three Years JC Gutierrez-Ramos, CEO Group SVP Biotherapeutics, Pfizer SVP, Head Immunoinflammation Center for Drug Discovery, GSK CSO & Site Head, Amgen Mountain View Dean Falb, CTO Entrepreneur in Residence, Atlas Venture VP,
Slide 7: Synthetic Biotic Broad Platform and Pipeline Potential
Synthetic Biotic Broad Platform and Pipeline Potential: Focus on Orphan Metabolic Diseases Immuno-Oncology (IO) Synthetic Biotic Platform Internal Pipeline Focus Immunomodulation Inflammatory Bowel Disease On-going Partnership Other Inflammation and Immunology Metabolic Diseases Rare Diseases Inborn
Slide 8: Synthetic Biotic Pipeline
Synthetic Biotic Pipeline Inborn Errors of Metabolism Metabolic Disease Immunomodulation Immuno Oncology 1 Indication Screening Lead Discovery Lead Optimization IND-Enabling Studies Phase I Hyperammonemia -Urea Cycle Disorder SYNB1020 Phenylketonuria SYNB1618 Organic Acidemias Maple Syrup Urine Dise
Slide 9: Synlogic's Initial Focus: Inborn Errors of Metabolism
Synlogic’s Initial Focus: Inborn Errors of Metabolism Disease Toxic Metabolite Urea Cycle Disorders Ammonia Phenylketonuria Phenylalanine Organic Acidemias Propionate Maple Syrup Urine Disease Ile, Leu, Val Clinical Candidates Lead Optimization ~25K cases in the US
Slide 10: SYNB1020 for Hyperammonemia
SYNB1020 for Hyperammonemia Indications: Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE) H H H N Protein Metabolism (food, muscles, etc.) Ammonia Buildup (toxic levels) Urea (removed from the body normally) Ammonia Liver Healthy ! Hepatic Encephalopathy: Sub-population of cirrhosis patien
Slide 11: SYNB1020: Conversion of Toxic Ammonia into Arginine
Probiotic bacteria: E. coli Nissle SYNB1020: Conversion of Toxic Ammonia into Beneficial Arginine for the Treatment of UCD and HE Synthetic Biotic Medicine Correct the deficiency ✓ UCD and HE Patients Target Profile: Normalize Ammonia Levels Dietary Protein Liberalization Without Systemic Toxicity A
Slide 12: Efficient Ammonia Conversion: In Vitro and In Vivo
Efficient Ammonia Conversion: In Vitro and In Vivo Blood Ammonia Reduced in vivo (spf-ash hyperammonia/UCD model on High Protein Diet) 0 100 50 150 200 250 Blood Ammonia (uM) Water/NC Water/HP SYNB1010/HP *** NC – Normal chow, HP – High protein chow SYNB1010 – arg producing, Thy A auxotrophy, Kan re
Slide 13: SYNB1020: Toxicology Package and Regulatory Path
SYNB1020: Toxicology Package and Regulatory Path Regulatory Orphan Drug Designation Pre-IND Meeting Feedback from FDA Office of Vaccines Research and Review No Recombinant DNA Advisory Committee (RAC) CMC plan for the Phase 1/2 studies Non-Clinical plan: dose selection; single species tox; single au
Slide 14: From Flask to Industrial Fermenter at CMO
From Flask to Industrial Fermenter at CMO: Well-Controlled Process at 150L Successful Scale-up to Biomass for Clinical Scale Number of doses at 1e12 CFU 10000 1000 100 10 Shake flask – 250 mL Shake flask – 500 mL Shake flask – 1 L Bench fermenter – 5 L Pilot fermenter – 25 L Pilot fermenter – 150 L
Slide 15: SYNB1020: Phase 1 SAD/MAD in Healthy Volunteers
Estimated start mid-2017 Traditional SAD/MAD design assessing safety, tolerability and kinetics in healthy volunteers across a range of doses Includes exploratory biomarkers in the context of controlled calorie and protein diet Complete urine and fecal collection Blood ammonia and amino acid profile
Slide 16: SYNB1020 Strategy in Hyperammonemia
SYNB1020 Strategy in Hyperammonemia: Following Success in Healthy Volunteers, Two Patient Studies Planned Phase 2 UCD and/or HE Phase 1b UCD Goal: Demonstrate safety/tolerability in UCD patients Phase 1b/2a Cirrhosis with Elevated Ammonia Goal: Establish safety/tolerability and POC in patients (redu
Slide 17: SYNB1618: Phenylketonuria (PKU) Overview
SYNB1618: Phenylketonuria (PKU) Overview Protein Metabolism (food, muscles, etc.) Phenylalanine Buildup (toxic levels) Tyrosine (used by body normally) Phenylalanine Liver Healthy PKU ! PKU disorders: 16,500 patients with hereditary disorder (U.S.) Genetic defect in phenylalanine hydrolase (PAH) enz
Slide 18: SYNB1618: Degradation of Toxic Phenylalanine for PKU
SYNB1618: Degradation of Toxic Phenylalanine for the Treatment of PKU Probiotic bacteria: E. coli Nissle Synthetic Biotic Medicine Correct the deficiency ✓ Phenylalanine t-Cinnamic Acid Synthetic Genetic Circuit Phenylalanine t-Cinnamic Acid Metabolic Conversions High-Affinity Uptake LAAD Phenylketo
Slide 19: PKU: Efficient Phe Degradation In Vitro and In Vivo
PKU: Efficient Phe Degradation In Vitro and In Vivo With pheP Transporter Without pheP Transporter 20 10 10 0 5 Phe Degradation Rate (μmoles/h/10e9cells) Integration Site PAL copy Number Integration Site PAL copy Number pheP copy Number LAAD + 3XPAL + pheP+ PAL – Convert Phe to TCA pheP – Transport
Slide 20: PKU: Urinary Hippurate as a Biomarker
PKU: Urinary Hippurate as a Biomarker for Synthetic Biotic Program Activity Urinary Hippurate (umol), 0-6 h Increased Urinary Hippurate in NHP Following Treatment with Synthetic Biotic Program *Average quantity of hippurate recovered per cage Increased Urinary Hippurate in Mice Following Treatment w
Slide 21: SYNB1618: Clinical Candidate for PKU
SYNB1618: Clinical Candidate for PKU Traditional SAD/MAD design assessing safety, tolerability and kinetics in healthy volunteers (HV) across a range of doses Includes a cohort of 8 PKU patients Proof of Mechanism: Hippurate production in HV Will assess reduction in plasma phenylalanine SYNB1618: Pl
Slide 22: Key Inflection Points and Estimated Timing
Key Inflection Points and Estimated Timing: SYNB1020 and SYNB1618 SYNB1020 Estimated Timing: Mid-2017: HV: Safety, tolerability, kinetics First half of 2018: Cirrhosis patients with elevated ammonia initiates: Safety/tolerability and POC in patients (reduction of ammonia) Mid 2018: UCD patient cohor
Slide 23: Synthetic Biotic Medicines: Applicability Beyond Rare Disease
Synthetic Biotic Medicines: Applicability Beyond Rare Disease Across Multiple Pathways in Metabolic & Autoimmune Diseases and Immuno Oncology Short Chain Fatty Acids: Butyrate Acetate Propionate Proteins and Peptides IL2, IL12, IL15, IL22,IL10 IFN, TNF, CXCL10, CD40L, hyaluronidase GLP1, GLP2 Amino
Slide 24: SYNLOGIC
SyNIOgIC |
Slide 25: Synlogic Overview
Synlogic Overview Novel Therapeutic Class Robust Pipeline with Orphan Drug Programs Broad Platform - Multiple Product Opportunities Dominant Synthetic Biotic IP Portfolio As of May 2017 Strong Balance Sheet Synthetic Biotic Platform: Leading in the use of synthetic biology to genetically reprogram b
Mirna Therapeutics — Merger or Acquisition (June 2017) on 6ix